Project MIX: Behavioral Intervention to Reduce Risk Among Substance-Using MSM
NCT ID: NCT00153361
Last Updated: 2024-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1686 participants
INTERVENTIONAL
2002-10-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men
NCT00691496
A SYNdemic BASed INtervention for MSM With High Risk Behavior: Design of a Randomized Controlled Trial
NCT02859935
Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)
NCT01279044
Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States
NCT02663219
Risk Reduction for Urban Substance Using Men Who Have Sex With Men (MSM)
NCT01327898
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sexual risk reduction interventions for MSM identified in the published scientific literature have demonstrated that they are generally effective at reducing sexual risk behaviors among MSM. However, none of these interventions specifically targeted non-injecting SUMSM. Thus, a gap exists in prevention efforts to reduce HIV transmission among SUMSM.
The primary aim of the Project Mix overall is to develop and evaluate a practical intervention strategy that is specifically tailored to the needs of non-injecting SUMSM. The intent of the intervention is to decrease the number of unprotected anal sex partners (and acts) while under the influence of AOD and in general.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Behavioral discussion sessions focused on reducing substance use and sexual risk behavior
Discussion Group
Comparison
Video discussion on health issues unrelated to HIV prevention and substance use
Video Discussion Group
Control
Waitlist control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Discussion Group
Video Discussion Group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* self-identify as male;
* understand and read English;
* live within the metropolitan area;
* report being drunk or "buzzed" on alcohol 2 or more times or high on non-injection drugs at least once during (or two hours before) anal sex in the past six months;
* have had at least one unprotected anal sex episode in the past six months with a male partner of unknown or different HIV-status than their own (i.e., DUA)
Exclusion Criteria
* report injecting drugs (eligible if only methamphetamine, steroids, hormones and/or prescribed medications) in the past six months;
* have known their HIV-positive status for less than six months (this is done to allow for psychological and behavioral adjustment following an initial HIV diagnosis and this time frame coincides with our screening window); these men (if they so desire) will be put on a wait list and contacted after 6 months have passed since their first HIV-positive test result;
* are currently involved in another HIV behavioral intervention study for MSM \[local study site identifies a list of such studies in their community at the time of the trial\];
* have a specific plan to move from the metropolitan area within the next 15 months;
* participated in the pilot phase of the project;
* other reasons that the investigators deem would make participation either detrimental to the participant or to the study.
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York Blood Center
OTHER
San Francisco Department of Public Health
OTHER_GOV
University of Illinois at Chicago
OTHER
Health Research Association
OTHER
Gordon Mansergh
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gordon Mansergh
Project Officer/Senior Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gordon Mansergh, PhD
Role: PRINCIPAL_INVESTIGATOR
Centers for Disease Control and Prevention
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Health Research Association
Hollywood, California, United States
San Francisco Department of Public Health
San Francisco, California, United States
The University of Illinois at Chicago
Chicago, Illinois, United States
Howard Brown Health Center
Chicago, Illinois, United States
New York Blood Center
New York, New York, United States
Project Achieve
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mansergh G, Koblin BA, McKirnan DJ, Hudson SM, Flores SA, Wiegand RE, Purcell DW, Colfax GN; Project MIX Study Team. An intervention to reduce HIV risk behavior of substance-using men who have sex with men: a two-group randomized trial with a nonrandomized third group. PLoS Med. 2010 Aug 24;7(8):e1000329. doi: 10.1371/journal.pmed.1000329.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U65/CCU522209
Identifier Type: -
Identifier Source: secondary_id
U65/CCU922215
Identifier Type: -
Identifier Source: secondary_id
U65/CCU222309
Identifier Type: -
Identifier Source: secondary_id
U65/CCU922213
Identifier Type: -
Identifier Source: secondary_id
CDC-NCHSTP-3985
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.